Soberana 02
Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoCovac (Persian: پاستوکووک) in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.[1][2][3]
Vaccine description
Pasteur
FINLAY-FR-2
Pasteurcovac, Pasto Covac, پاستوکووک
- Full and emergency authorizations
It is a conjugate vaccine that requires two doses, the second one being administered 28 days after the first shot.[4] A third (booster) dose of Soberana Plus may also be given on day 56. It has received emergency use authorization in Iran on June 2021, and in Cuba on August 2021, where it has also been approved for children above 2 years old.[5]
The name of the vaccine, Soberana, is a Spanish word that means "sovereign".[6] It followed a previous candidate vaccine called SOBERANA-01 (FINLAY-FR-1).[7]
Pharmacology[edit]
FINLAY-FR-2 is a conjugate vaccine. It consists of the receptor binding domain of the SARS-CoV-2 spike protein conjugated chemically to tetanus toxoid.[7]
Professor Ihosvany Castellanos Santos said that the antigen is safe because it contains parts instead of the whole live virus, and therefore it does not require extra refrigeration, like other candidates in the world.[19]